{'fraction_non_alphanumeric': 0.03553581343697946, 'fraction_numerical': 0.03053858967240422, 'mean_word_length': 5.1084745762711865, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Association Between Diabetes Mellitus With Five-Year Survival Rate of Breast Cancer Patients

Background: Breast cancer is a highly prevalent malignancy leading to death across the world. However, patient survival is greatly affected by making a diabetes diagnosis. The present study aimed to assessment the association between diabetes mellitus with five-year survival rate of breast cancer patients at the cancer treatment centers. Methods: This Retrospective follow‐up study was conducted on diabetic women with breast cancer. This Retrospective follow‐up study was conducted on 534 women with breast cancer, who had been diagnosed during 1999-2013 referred to cancer treatment centers of Mashhad University of Medical Sciences. Demographic and clinical data of patients were collected through questionnaires in these centers searching the patient's available medical files. Notably, the patients were selected via systematic random sampling and also the five-year survival of the patients was assessed during the follow-up period up to 2018. Results: In the breast cancer patients, the diabetes prevalence was 12.7%. Of note, the mean and median of five-year survival were 9.95 and 13, respectively. No significant difference was observed in the survival rate of the diabetic and non-diabetic patients (95% CI: 0.431-1.334; hazard ratio [HR]: 0.758; P=0.34). The survival time was increased in the patients receiving metformin as a treatment protocol (95% CI: 0.226-0.950; HR: 0.5; P=0.04). Conclusion: Based on the results, training diabetic patients in regard to risk factors of the breast cancer and effective therapies in controlling hyperglycaemia that need to screen in the early diagnosis of breast cancer are essential to improve health and increase survival rate in diabetic patients.